Candida Auris Features and its Treatment

AlJindan R, Al Eraky DM. Silver nanoparticles: A promising antifungal agent against the growth and biofilm formation of the emergent Candida auris. J Fungi 2022; 8: 744. https://doi.org/10.3390/ jof8070744.

Alvarado-Socarras JL, Vargas-Soler JA, Franco-Paredes C, Villegas-Lamus KC, Rojas-Torres JP, Rodriguez-Morale AJ. A cluster of neonatal infections caused by Candida auris at a large referral center in Colombia. J Pediatr Infect Dis Soc 2021; 10:549–55. doi: 10.1093/jpids/piaa152.

ANVISA-2022. https://mundoeducacao.uol.com.br/doencas/candida-auris.htm.

Arendrup MC, Chowdhary A, Astvad KMT, Jorgensen KM. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother 2018; 62:e01225. doi: 10.1128/AAC.01225-18.

Arif S, Batool A, Khalid N, Ahmed I, Janjua HA. Comparative analysis of stability and biological activities of violacein and starch capped silver nanoparticles. RSC Adv 2017; 7: 4468–4478. https://doi.org/10.1039/C6RA25806A.

Ashkenazi-Hoffnung L, Rosenberg Danziger C. Navigating the new reality: a review of the epidemiological, clinical, and microbiological characteristics of Candida auris, with a focus on children. J. Fungi 2023; 9:176. DOI: 10.3390/jof9020176.

Barreto ES, Torres AR, Barreto MR, Vasconcelos ATR, Astolfi-filho S, Hungria M. Diversity in antifungal activity of strains of Chromobacterium violaceum from the Brazilian Amazon. J Ind Microbiol Biotechnol 2008; 35, 783–790. DOI:10.1007/s10295-008-0331-z.

Bidaud AL, Botterel F, Chowdhary A, Dannaoui E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob. Agents Chemother 2019; 63:e01393. DOI: 10.1128/AAC.01393-19.

Break TJ, Desai JV, Natarajan M, Ferre EMN, Henderson C, Zelazny AM, et al. VT-1161 Protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and-resistant Candida albicans. J Antimicrob Chemother 2018b; 73 151–155. doi: 10.1093/jac/dkx352.

Break TJ, Desai JV, Healey KR, Natarajan M, Ferre EMN, Henderson C, et al. VT-1598 inhibits the in vitro growth of mucosal candida strains and protects against fluconazole-susceptible and-resistant oral candidiasis in IL-17 signaling-deficient mice. J Antimicrob Chemother 2018a;73: 2089–2094. doi: 10.1093/jac/dky170.

Bhargava A, Klamer K, Sharma M, Ortiz D, Saravolatz L. Candida auris: A continuing threat. Microorganisms 2025; 13: 652. https://doi.org/10.3390/ microorganisms13030652.

Bruno VM, Kalachikov S, Subaran R, Nobile CJ, Kyratsous C, Mitchell AP. Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. PLOS Pathog 2006; 2:e21. https://doi.org/10.1371/journal.ppat.0020021.

Caballero U, Eraso E, Quindos G, et al. PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris. CPT Pharmacomet Syst Pharmacol 2023; 12:770–82. https://doi.org/10.1002/psp4.12949.

Caballero U, Eraso E, Quindos G, Jauregizar N. In vitro interaction and killing-kinetics of amphotericin B combined with anidulafungin or caspofungin against Candida auris. Pharmaceutics 2021; 13:1333. DOI: 10.3390/pharmaceutics13091333.

Carolus H, Sofras D, Boccarella G, Sephton-Clark P, Biriukov V, Cauldron NC, et al. Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris. Nat Microbiol 2024; 9:3304–3320. https://doi.org/1 0.1038/s41564-024-01854-z.

CDC-2023: https://www.weforum.org/stories/2023/04/candida-auris-what-you-need-to-know-about-the-deadly-fungus-spreading-through-us-hospitals/

Cha H, Won D, Kang S, Kim E-S, Lee K-A, Lee W-J, Lee K-T, Bahn Y-S. The calcineurin pathway regulates extreme thermotolerance, cell membrane and wall integrity, antifungal resistance, and virulence in Candida auris. bioRxiv. 2025; https://doi.org/10.1101/2025.01.02.631159.

Chanda, W., Joseph, T. P., Wang, W., Padhiar, A. A., and Zhong, M. The potential management of oral candidiasis using anti-biofilm therapies. Med Hypotheses 2017; 106: 15–18. doi: 10.1016/j.mehy.2017.06.029.

Chen J, Tian S, Han X, et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect. Dis 2020; 20:827. https://doi.org/10.1186/s12879-020-05543-0.

Chow EWL, Song Y, Chen J, Xu X, Wang J, Chen K, et al. The transcription factor Rpn4 activates its own transcription and induces efflux pump expression to confer fluconazole resistance in Candida auris. mBio 2023; 14:e0268823. https://doi.org/10.1128/mbio.02688-23.

Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis 2020; 26:2694–96. doi: 10.3201/eid2611.203504.

Contaldo M. Use of probiotics for oral candidiasis: state of the art and perspective. A further step toward personalized medicine? Front Biosci 2023; 15:6. doi: 10.31083/j.fbe1501006.

Contaldo M, Di Stasio D, Romano A, Fiori F, Della Vella F, Rupe C, et al. Oral candidiasis and novel therapeutic strategies: antifungals, phytotherapy, probiotics, and photodynamic therapy. Curr Drug Deliv 2023; 20: 441–456. doi: 10.2174/1567201819666220418104042.

Costa-de-Oliveira S, Rodrigues AG. Candida albicans antifungal resistance and tolerance in bloodstream infections: the triad yeast-host antifungal. Microorganisms 2020; 8:154. https://doi.org/10.3390/microorganis ms8020154.

Davi Marena G, Nosanchuk JD, Taborda CP. Candidozyma auris Alert in South America: An Epidemiological and therapeutic update. Curr Trop Med Rep 2025; 12: 1. https://doi.org/10.1007/s40475-024-00338-8.

De Bernardis, F., Amacker, M., Arancia, S., Sandini, S., Gremion, C., Zurbriggen, R., et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 2012; 30: 4490–4498. doi: 10.1016/ j.vaccine.2012.04.069.

Desai JV, Break TJ, Natarajan M, Henderson C, Zelazny AM, Hoekstra WJ, et al. VT-1129 and VT-1161 have in vitro activity against candida isolates from patients with chronic mucocutaneous candidiasis. Open Forum Infect. Dis. 2016; 3: (suppl_1). doi: 10.1093/ofid/ofw172.1335.

Dike-Ndudim JN, Ugenyi LC, Ndubueze CW. Assessment of antifungal potentials of violacein extract from Chromobacterium violaceum isolated from domestic and recreational water sources in Owerri, Imo state. Nigeria World J Adv Res Rev 2021; 10: 168–172. https://doi.org/10.30574/wjarr.2021.10.3.0243.

Durán N, Favaro WJ, Brocchi M, Justo GZ, Castro GR, Durán, M, et al. Patents on violacein: a compound with great diversity of biological activities and industrial potential. Recent Patent Biotechnol 2021a; 15: 102 111. DOI: 10.2174/2213476X07666201221111655.

Durán N, Nakazato G, Durán M, Berti IR, Castro GR, Stanisic D, et al. Multi-target drug with potential applications: Violacein in the spotlight. World J Microbiol Biotechnol 2021b; 37: 151. DOI: 10.1007/s11274-021-03120-4.

Durán N, Fávaro WJ, de Castro SC, Nakazato G, Castro GR, Justo GZ, et al. Violacein: New advances in production, purification, and actual biological activities. J. Brazil Chem Soc Submitted, 2025.

Durán N, Castro GR, Portela RWD, Fávaro WJ, Durán M, Tasic L, et al. Violacein and its antifungal activity: Comments and potentialities. Lett Appl Microbiol 2022; 75: 796-803. doi:10.1111/lam.13760.

Edwards Jr JE, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, et al. A Fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-A Phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2018; 66: 1928–1936. doi: 10.1093/cid/ciy185.

Eix EF, Nett JE. Candida auris: Epidemiology and antifungal strategy. Annu Rev Med 2025; 76: 57–67. doi:10.1146/annurev-med-061523-021233.

El Ayoubi LEW, Allaw F, Moussa E, Kanj SS. Ibrexafungerp: A narrative overview. Curr Res Microb Sci 2024; 6: 100245. https://doi.org/10.1016/j.crmicr.2024.100245.

Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E, Meis JF, et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob. Agents Chemother 2017; 61:e01056. https://doi.org/10.1128/aac.01056-17.

Fayed B. Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects. Drug Deliv Trans Res; 2025; 15: 1496–1512 https://doi.org/10.1007/ s13346-024-01749-w.

Fusco A, Contaldo M, Savio V, Baroni A, Ferraro GA, di Stasio D, et al. An unconventional oral Candidiasis in an immunocompetent patient. J Fungi 2023; 9:295. doi: 10.3390/jof9030295.

Gao A, Chena H, Houb A, Xie K. Efficient antimicrobial silk composites using synergistic effects of violacein and silver nanoparticles. Mat Sci Eng C 2019; 103: 109821. https://doi.org/10.1016/j.msec.2019.109821.

Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL. Efficacy of the clinical agent VT-1161 against fluconazole sensitive and-resistant Candida albicans in a murine model of vaginal Candidiasis. Antimicrob Agents Chemother 2015; 59: 5567–5573. doi: 10.1128/ AAC.00185-15.

Govender NP, Avenant T, Brink A, Chibabhai V, Cleghorn J, du Toit B, et al. Federation of Infectious Diseases Societies of Southern Africa guideline: Recommendations for the detection, management and prevention of healthcare-associated Candida auris colonisation and disease in South Africa. S Afr J Infect Dis 2019; 34:163. doi: 10.4102/sajid.v34i1.163. eCollection 2019.

Grant VC, Nguyen K, Rodriguez S, Zhou AY, Abdul-Mutakabbir JC, Tan KK. Characterizing safety and clinical outcomes associated with high-dose micafungin utilization in patients with proven invasive candidiasis. Trop Med Infect Dis 2022; 7:23. doi: 10.3390/tropicalmed7020023.

Gu K, Spitz R, Hammett E, Jaunarajs A, Ghazaryan V, Garvey EP, et al. Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598. Med Mycol 2024; 62: myae032. https://doi.org/10.1093/mmy/myae032.

Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 2014; 24: 3455–3458. doi: 10.1016/ j.bmcl.2014.05.068.

Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely O, Krause R, et al. The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021; 81: 1703–1729. doi: 10.1007/s40265-021-01611-0.

Huang X, Dong Q, Zhou Q, Fang S, Xu Y, Long H, et al. Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance. Front Microbiol 2025; 16:1531543. doi: 10.3389/fmicb.2025.1531543.

Hospital-SP-2025. https://www.uol.com.br/vivabem/noticias/redacao/2025/04/02/entenda-o-superfungo-que-infectou-15-pacientes-em-hospital-de-sao-paulo.htm?cmpid= copiaecola).

ICU-2025. https://www.cbnrecife.com/artigo/Primeiro-caso-de-candida-auris-em-2025-e-confirmado-em-pernambuco.

Jain K, Mishra B, Tiwari A, Siddiqui SI, Areeshi MY, Haque S. Antifungal potency of biosynthesized silver nanoparticles derived from marine diatoms against multidrug-resistant Candida auris and Pichia kudriavzevii. ChemistrySelect, 2025; 10: e202404088. https://doi.org/10.1002/slct.202404088.

Jia Y, Tang RJ, Wang L, Zhang X, Wang Y, Jia XM, et al. Calcium activated-calcineurin reduces the in vitro and in vivo sensitivity of fluconazole to Candida albicans via Rta2p. PLoS One 2012; 7:e48369. https://doi.org/10.1371/journal.pone.0048369.

John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP, Harrison TS, et al. Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro. Antimicrob Agents Chemother 2023; 67: e01645-22. https://doi.org/10.1128/aac.01645-22.

Kanelli M, Mandic M, Kalakona M, Vasilakos S, Kekos D, Nikodinovic-Runic J, et al. Microbial production of violacein and process optimization for dyeing polyamide fabrics with acquired antimicrobial properties. Front Microbiol 2018; 9: 1495. doi: 10.3389/fmicb.2018.01495. eCollection 2018.

Kim JS, Lee KT, Bahn YS. Deciphering the regulatory mechanisms of the cAMP/protein kinase A pathway and their roles in the pathogenicity of Candida auris. Microbiol Spectr 2023; 11:e0215223. https://doi.org/10.11 28/spectrum.02152-23 27.

Kim JS, Lee KT, Lee MH, Cheong E, Bahn YS. Adenylyl cyclase and protein kinase A play redundant and distinct roles in growth, differentiation, antifungal drug resistance, and pathogenicity of Candida auris. mBio 2021; 12: e0272921. https://doi.org/10.1128/mBio.02729-21.

Koleri J, Petkar HM, Al Soub HARS, Al Maslamani MARS. Candida auris blood stream infection—a descriptive study from Qatar. BMC Infect. Dis 2023; 23:513. doi: 10.1186/s12879-023-08477-5.

Kordalewska M, Cancino-Prado G, Nobrega de Almeida Júnior J, Brasil Brandão I, Tigulini de Souza Peral R, Colombo AL, et al. DS. Novel non-hot spot modification in Fks1 of Candida auris confers echinocandin resistance. Antimicrob Agents Chemother 2023; 67:e0042323. https://doi.org/ 10.1128/aac.00423-23.

Lara HH, Ixtepan-Turrent L, Yacaman MJ, Lopez-Ribot J. Inhibition of Candida auris biofilm formation on medical and environmental surfaces by silver nanoparticles. ACS Appl Mater Interf 2020; 12: 19. https://doi.org/10.1021/acsami.9b20708.

Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. Pharmacodynamic optimization for treatment of invasive Candida auris infection. Antimicrob. Agents Chemother 2017; 61:e00791/. doi: 10.1128/AAC.00791-17.

Lepak AJ, Zhao M, Andes DR. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. Antimicrob. Agents Chemother 2018; 62: e01572. https://doi.org/10.1128/aac.01572-18.

Li J, Coste AT, Liechti M, Bachmann D, Sanglard D, Lamoth F. Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris. Antimicrob Agents Chemother 2023; 65:e02663-20. https://doi.org/10.11 28/AAC.02663-20.

Li J, Coste AT, Bachmann D, Sanglard D, Lamoth F. 2022. Deciphering the Mrr1/Mdr1 pathway in azole resistance of Candida auris. Antimicrob Agents Chemother 2022; 66:e0006722. https://doi.org/10.1128/aac.00067-22.

Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell 2011; 10: 168–173. doi: 10.1128/EC.00279-10.

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017; 64:134–40. doi: 10.1093/cid/ciw691.

Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med 2023; 176:489–95. doi: 10.7326/M22-3469.

Millar, E. V., Bennett, J. W., Barin, B., Carey, P. M., Law, N. N., English, C. E., et al. Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US army infantry trainees. Vaccine 2021; 39: 3179–3188. doi: 10.1016/j.vaccine.2021.04.031.

Monk BC, Keniya MV, Sabherwal M, Wilson RK, Graham DO, Hassan HF, et al. Azole resistance reduces susceptibility to the tetrazole antifungal VT-1161. Antimicrob Agents Chemother 2019; 6: 1–19. doi: 10.1128/AAC.02114-18.

Murphy SE, Bicanic T. Drug resistance and novel therapeutic approaches in invasive Candidiasis. Front Cell Infect Microbiol 2021; 11:759408. doi: 10.3389/fcimb.2021.759408.

Nakazato G, Fávaro WJ, Castro GR, Durán N. The Use of Candida auris therapies based on nanotechnology as potential novel strategy against COVID-19 infection: A mini review. AIRJ Preprints, Section: Coronavirus Article Id: 337, 2021. DOI: https://doi.org/10.21467/preprints.337.

Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morschhäuser J, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother 2019; 63: 1–11. doi: 10.1128/AAC.00341-19.

O’Brien B, Chaturvedi S, Chaturvedi V. In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. Antimicrob Agents Chemother 2020; 64:e02195. https://doi.org/10.1128/aac.02195-19.

Ohashi Y, Matono T, Suzuki S, Yoshino S, Alshahni MM, Komori A, et al. The first case of clade I Candida auris candidemia in a patient with COVID-19 in Japan. J Infec Chemother. 2023; 29: 713–717. https://doi.org/10.1016/j.jiac. 2023.03.018.

Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, et al. Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. Intern Med J 20119; 49:1229–43. https://doi.org/10.1111/imj.14612.

Ostrowsky B, Greenko J, Adams E, Quinn , O’Brien B, Chaturvedi V, et al. Candida auris isolates resistant to three classes of antifungal medications—New York, 2019. Morb Mortal Wkly Rep 2020; 69:6–9. doi: 10.15585/mmwr.mm6901a2.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichne L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1 50. https://doi.org/10.1093/cid/civ933.

Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol. 2007, 5, e64. doi: 10.1371/journal.pbio.0050064.

Price TK, Mirasol R, Ward KW, Dayo AJ, Hilt EE, Chandrasekaran S, et al. Genomic characterizations of clade III lineage of Candida auris, California, USA. Emer Infec Dis 2021; 27: 1223-1227. DOI: https://doi.org/10.3201/eid2705.204361.

Ricci L, Mackie J, Donachie GE, Chapuis A, Mezerová K, Lenardon MD, et al. Human gut bifidobacteria inhibit the growth of the opportunistic fungal pathogen Candida albicans. FEMS Microbiol Ecol 2022; 98:95. doi: 10.1093/femsec/fiac095.

Ruiz-Gaitán A, Martínez H, Moret AM, Calabuig E, Tasias M, Alastruey-Izquierdo A, et al. Detection and treatment of Candida auris in an outbreak situation: Risk factors for developing colonization and candidemia by this new species in critically ill patients. Expert Rev Anti-Infect Ther 2019; 17:295–305. doi: 10.1080/14787210.2019.1592675.

Sahu SR, Bose S, Singh M, Kumari P, Dutta A, Utkalaja BG, et al. Vaccines against candidiasis: Status, challenges, and emerging opportunity. Front Cell Infect Microbiol 2022; 12:1002406. doi: 10.3389/fcimb.2022.1002406.

Sasidharan A, Sasidharan NK, Amma DBNS, Vasu RK, Nataraja AV, Bhaskaran K. Antifungal activity of violacein purified from a novel strain of Chromobacterium sp. NIIST (MTCC 5522). J Microbiol 2015; 53: 694–701. doi: 10.1007/s12275-015-5173-6.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53:41e4. https://doi:10.1111/j.1348-0421.2008.00083.x.

Schell WA, Jones AM, Garvey EP, Hoekstra WJ, Schotzinger RJ, Alexander BD. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother 2017a; 61: 1–3. doi: 10.1128/AAC.01817-16.

Schmidt, C. S., White, C. J., Ibrahim, A. S., Filler, S. G., Fu, Y., Yeaman, M. R., et al. NDV-3, a recombinant alum-adjuvanted vaccine for candida and staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012; 30: 7594–7600. doi: 10.1016/j.vaccine.2012.10.038.

Sekizuka T, Iguchi S, Umeyama T, Inamine Y, Makimura K, Kuroda M, et al. Clade II Candida auris possess genomic structural variations related to an ancestral strain. PLoS ONE 2019; 14: e0223433. https://doi.org/10.1371/journal. pone.0223433.

Shivarathri R, Jenull S, Stoiber A, Chauhan M, Mazumdar R, Singh A, et al. The two-component response regulator Ssk1 and the mitogen-activated protein kinase Hog1 control antifungal drug resistance and cell wall architecture of Candida auris. mSphere 2020; 5:e00973-20. https://doi.org/10.1128/mSpher e.00973-20.

Sindhu R, Bhat SS, Sangta J, Dharmashekar C, Shreevatsa B, Shivamallu C, et al. Gaining molecular insights towards inhibition of foodborne fungi Aspergillus fumigatus by a food colourant violacein via computational approach. Sci Rep 2024; 14:29905, https://doi.org/10.1038/s41598-024-81471-2.

Singh S, Uppuluri P, Mamouei Z, Alqarihi A, Elhassan H, French S, et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathog. 2019; 15: e1007460.

Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006, 194, 256–260. doi: 10.1086/504691.

Spruijtenburg B, Badali H, Abastabar M, Mirhendi H, Khodavaisy S, Shari?sooraki J, et al. Confirmation of fifth Candida auris clade by whole genome sequencing. Emerg Microbes Infect 2022; 11:2405–11. doi: 10.1080/22221751.2022.2125349.

Suphavilai C, Ko KKK, Lim KM, Tan MG, Boonsimma P, Chu JJK, et al. Detection and characterisation of a sixth Candida auris clade in Singapore: a genomic and phenotypic study. Lancet Microbe 2024; 5: 100878. https://doi.org/10.1016/ S2666-5247(24)00101-0.

Thompson GR, King T, Azie N, Angulo DA, Prattes J. Oral Ibrexafungerp Outcomes by fungal disease in patients from an interim analysis of a phase 3 open-label study (FURI), Open Forum Infectious Diseases (OFID) 2022:9 (Suppl 2), S41. DOI:10.1093/ofid/ofac492.064.

Verma N, Riyaz M, Kaur G, Negi P, Ghawri H, Raj K. Anticandidal efficacy of green synthesized silver nanoparticles using Trans-Himalayan plant extracts against drug resistant clinical isolates of Candida auris. Indian J Microbiol 2024; 64: 1912–1928. https://doi.org/10.1007/s12088-024-01277-8.

Vazquez-Muñoz R, Lopez FD, Lopez-Ribot JL. Silver nanoantibiotics display strong antifungal activity against the emergent multidrug-resistant yeast Candida auris under both planktonic and biofilm growing conditions. Front Microbiol 2020a; 11:1673. doi: 10.3389/fmicb.2020.01673.

Warrilow AGS, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother 2014; 58: 7121–7127. doi: 10.1128/AAC.03707-14.

Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, et al. The fungal CYP51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother 2019; 63:e02233-18. https://doi .org/10.1128/AAC.02233-18.

World & Nation-2025. https://www.latimes.com/world-nation/story/2025-03-27/deadly-drug-resistant-fungus-cdc-calls-urgent-threat-is-spreading-in-hospitals.

Zhao G, Lyu J, Veniaminova NA, Zarnowski R, Mattos E, Johnson CJ, et al. Candida auris skin colonization is mediated by Als4112 and interactions with host 2 extracellular matrix proteins. bioRxiv preprint doi: https://doi.org/10.1101/2025.02.13.637978. this version posted February 13, 2025.